A US NNSA nonproliferation program converted the world's major medical-isotope (Mo-99) producers off weapons-usable HEU targets to low-enriched uranium

Molybdenum-99, the medical isotope behind most nuclear-medicine scans, was historically produced by irradiating targets made of highly enriched uranium (HEU) — the same weapons-usable material a proliferator would want. This placed a live nonproliferation risk inside ordinary hospital supply logistics. Following a commitment made at the 2012 Nuclear Security Summit, the US National Nuclear Security Administration (NNSA) funded global Mo-99 producers (in countries including Belgium, South Africa, and the Netherlands) to switch their targets to low-enriched uranium (LEU). Per the NNSA, at the milestone it announced, "all major global molybdenum-99 (Mo-99) production facilities now use LEU targets."

The program is a deliberate convergence of arms-control policy and civilian medicine: the fix for a proliferation hazard was routed through the world's cancer-imaging supply chain rather than through a weapons treaty. It is the same HEU→LEU down-substitution logic — remove the weapons-usable material, keep the civilian function — that operated at vastly larger scale in Megatons to Megawatts, though here the point is denaturing the feedstock of production rather than blending down dismantled warhead stock.

The same Mo-99 supply chain is also what floods the CTBTO's test-detection network with civilian xenon-133 — see claim-ctbto-radioxenon-monitoring-confounded-by-medical-isotope-production — so this one industry sits at the intersection of nuclear medicine, test-ban verification, and nonproliferation. The verification contrast between the two regimes is drawn out in claim-two-verification-regimes-sensor-vs-inspector-govern-the-same-fissile-material-lifecycle.